Form 4: Mural Oncology CFO Sells Shares for Tax Obligations

Mural Oncology's Chief Financial Officer, Adam D. Cutler, sold 7,148 ordinary shares at $2.09 each to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Adam D. Cutler, Chief Financial Officer of Mural Oncology plc (MURA), reported a transaction involving the sale of ordinary shares.
• On November 3, 2025, Mr. Cutler disposed of 7,148 ordinary shares at a price of $2.09 per share.
• The sale was non-discretionary and executed automatically to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• This transaction was conducted pursuant to a Rule 10b5-1(c) plan, which was entered into on December 22, 2023.
• The RSUs in question were granted to Mr. Cutler on December 14, 2023.
• Following this transaction, Mr. Cutler beneficially owns 99,290 ordinary shares, which includes 77,429 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a non-discretionary sale of shares to cover tax withholding obligations, pre-arranged under a Rule 10b5-1 plan, and does not indicate a change in management's outlook or confidence in the company.

Industry Context

This filing represents a routine insider transaction common across publicly traded companies, where executives sell a portion of vested equity awards to cover tax liabilities. It does not reflect a discretionary investment decision based on company performance or outlook.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in insider sentiment or company fundamentals.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by Mural Oncology's CFO to cover tax obligations related to RSU vesting, executed under a pre-arranged 10b5-1 plan. Such transactions are common and do not typically reflect a change in the insider's view of the company's prospects or fundamental value. Therefore, this filing provides no new information that would warrant a change in an investor's current 'hold' position.

Keywords

Mural Oncology, MURA, Form 4, Insider Transaction, CFO, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1 Plan